Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grey Wolf HealthTSXV:WOLF -2.86%52 ROC (Joel Greenblatt) % is 25.67% as of Mar. 2026, which is 29% below its 10-year median of 36.38. GuruFocus rates TSXV:WOLF with a GF Score™ of 52/100 and a GF Value™ of C$1.09 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 981 Drug Manufacturers companies, Grey Wolf Health ranks better than 79.61% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Grey Wolf Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 25.67%.
The historical rank and industry rank for Grey Wolf Health's ROC (Joel Greenblatt) % or its related term are showing as below:
TSXV:WOLF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10.31 Med: 36.38 Max: 255.54
Current: 37.52
During the past 5 years, Grey Wolf Health's highest ROC (Joel Greenblatt) % was 255.54%. The lowest was -10.31%. And the median was 36.38%.
TSXV:WOLF's ROC (Joel Greenblatt) % is ranked better than 79.61% of 981
companies
in the Drug Manufacturers industry
Industry Median: 11.46
vs TSXV:WOLF: 37.52
Grey Wolf Health's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Grey Wolf Health (TSXV:WOLF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Grey Wolf Health ROC (Joel Greenblatt) % Related Terms
Grey Wolf Health ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Grey Wolf Health's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:WOLF vs ROL, SCI, FTDR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's ROC (Joel Greenblatt) % falls into.
Grey Wolf Health ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 25.67% mean?
Grey Wolf Health (TSXV:WOLF) has a ROC (Joel Greenblatt) % of 25.67% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Grey Wolf Health and its competitors. This is 29% below median its historical median of 36.38. According to the industry distribution chart, Grey Wolf Health ranks #200 out of 981 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Grey Wolf Health's ROC (Joel Greenblatt) % too high?
Grey Wolf Health's current ROC (Joel Greenblatt) % of 25.67% is 29% below median its 10-year median of 36.38. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.46. Grey Wolf Health's value of 25.67% is 124% above this industry median. Based on the distribution chart, Grey Wolf Health ranks #200 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grey Wolf Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's ROC (Joel Greenblatt) % compare to ROL and SCI?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #200 out of 981 companies for ROC (Joel Greenblatt) %. This places Grey Wolf Health in the top 20% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.46. Grey Wolf Health's value of 25.67% is 124% above this benchmark. While the company's 10-year median is 36.38 vs. the industry median of 11.46, Grey Wolf Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current ROC (Joel Greenblatt) % of 25.67% is 124% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Grey Wolf Health and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current ROC (Joel Greenblatt) % is 25.67%, which is 29% below median its own 10-year median of 36.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.09, compared to a current price of C$1.70 — trading 56% above its estimated fair value. The current ROC (Joel Greenblatt) % is 25.67%, which is 29% below median its 10-year median of 36.38 and 124% above the Drug Manufacturers industry median of 11.46. Grey Wolf Health's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current ROC (Joel Greenblatt) % is 25.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.70 is trading 56% above its estimated GF Value™ of C$1.09.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
ROC (Joel Greenblatt) %: 25.67% (29% below median its 10-year median of 36.38)
GF Value™: C$1.09 vs. price of C$1.70 (56% above fair value)
Industry Position: 124% above the Drug Manufacturers median (#200 of 981)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
52GF Score
Get the complete analysis for TSXV:WOLF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
